Latest Stories
3 Stocks Under $50 We Think Twice About
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
3 of Wall Street’s Favorite Stocks Worth Your Attention
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
3 Reasons to Sell CTS and 1 Stock to Buy Instead
Since July 2025, CTS has been in a holding pattern, posting a small loss of 1.1% while floating around $42.87. The stock also fell short of the S&P 500’s 11.2% gain during that period.
Ladder Capital (LADR): Buy, Sell, or Hold Post Q3 Earnings?
Since July 2025, Ladder Capital has been in a holding pattern, posting a small return of 1.2% while floating around $10.99. The stock also fell short of the S&P 500’s 11.2% gain during that period.
2 Reasons to Avoid WK and 1 Stock to Buy Instead
Over the past six months, Workiva has been a great trade, beating the S&P 500 by 15.1%. Its stock price has climbed to $86.29, representing a healthy 26.4% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
3 Reasons to Sell CDW and 1 Stock to Buy Instead
CDW’s stock price has taken a beating over the past six months, shedding 24.8% of its value and falling to $136.22 per share. This may have investors wondering how to approach the situation.
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings?
Over the past six months, Abbott Laboratories’s shares (currently trading at $125.45) have posted a disappointing 7.9% loss, well below the S&P 500’s 11.2% gain. This may have investors wondering how to approach the situation.
2 Reasons PGNY is Risky and 1 Stock to Buy Instead
Over the past six months, Progyny has been a great trade, beating the S&P 500 by 5.2%. Its stock price has climbed to $25.68, representing a healthy 16.4% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
3 Reasons ADSK is Risky and 1 Stock to Buy Instead
Autodesk currently trades at $297.44 per share and has shown little upside over the past six months, posting a small loss of 4.6%. The stock also fell short of the S&P 500’s 11.2% gain during that period.
3 Reasons POWL Has Explosive Upside Potential
What a time it’s been for Powell. In the past six months alone, the company’s stock price has increased by a massive 51.4%, reaching $318.00 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.